SPRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spruce Biosciences, Inc (SPRB) is not a strong buy at this moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The company is facing significant financial challenges, with no revenue, declining net income, and negative EPS. Additionally, the recent termination of its agreement with Kaken Pharmaceutical introduces uncertainty about its future projects and collaborations. While the technical indicators show some positive momentum, the lack of strong trading signals and the absence of positive catalysts make this stock a hold rather than a buy.
The MACD histogram is positive at 1.703, indicating bullish momentum. RSI is at 72.244, which is neutral but approaching overbought territory. Moving averages are converging, suggesting indecision in price trends. The stock is trading above its pivot point of 66.089, with resistance levels at 75.299 and 80.989, and support levels at 56.879 and 51.189.
Analysts remain optimistic about the potential of Tralesinidase Alfa Enzyme Replacement Therapy for Sanfilippo Syndrome Type B, with a relatively derisked path to approval.
The termination of the agreement with Kaken Pharmaceutical introduces uncertainty about future collaborations and projects. Financial performance has significantly deteriorated, with no revenue and a sharp decline in net income and EPS.
In Q4 2025, revenue dropped to 0 (-100% YoY), net income fell to -$14,646,000 (-37.83% YoY), and EPS declined to -11.28 (-73.51% YoY). Gross margin also dropped to 0 (-100% YoY), indicating severe financial challenges.
Analysts have lowered price targets recently but maintain positive ratings. Citizens lowered the price target to $170 from $180, and H.C. Wainwright reduced it to $200 from $220, citing delays in therapy filing timelines.
